

Lanreotide Homecare Service in the UK

ADVANZ PHARMA commissioned homecare is available for Lanreotide in the UK. Please contact your local representative or email CommercialsupportUK-IE@advanzpharma.com for more information.

Useful Information from the Summary of Product Characteristics [1]

4.1 Therapeutic indications

Lanreotide ADVANZ PHARMA (Lanreotide acetate) 60 mg, 90 mg and 120 mg solution for injection in a prefilled syringe is indicated for [1]:

- *The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.*
- *The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.*
- *The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.*

4.2 Posology and method of administration

Method of administration

Lanreotide ADVANZ PHARMA solution for injection is administered by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.

For patients who receive a stable dose of Lanreotide ADVANZ PHARMA solution for injection, and after appropriate training, the product may be administered either by the patient or by a trained person. In case of self-injection, the injection should be given in the upper outer thigh.

The decision regarding administration by the patient or a trained person should be taken by a healthcare professional. [...]

The information contained in this medical letter is supplied as a medical information service by ADVANZ PHARMA in response to your specific request. Information provided by ADVANZ Pharma Medical Information should be viewed at all times alongside the SmPC. It should not constitute formal clinical advice. ADVANZ PHARMA only recommends the use of lanreotide as specified in the prescribing information officially approved by the regulatory authority of your country. For complete information on the safety of lanreotide, please refer to the approved prescribing information.

Last revision: 31 July 2023

References

1. Lanreotide ADVANZ PHARMA 60 mg, 90 mg or 120 mg solution for injection in a prefilled syringe, Medicines and Healthcare products Regulatory Agency (MHRA), Summary of Product Characteristics; available at <https://www.medicines.org.uk/emc/product/14483/smpc> (60mg); <https://www.medicines.org.uk/emc/product/14484/smpc> (90mg); <https://www.medicines.org.uk/emc/product/14485/smpc> (120mg); last access: 31 July 2023